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Although the reductionist approach has served sci-
ence well for 400 years, the accumulation of details 
can obscure the truth if the original premise is incor-
rect. One such premise has been that successful organ 
transplantation and bone marrow engraftment are 
fundamentally different outcomes involving separate 
and distinct mechanisms. Some historical clinical ob-
servations pointed to a different conclusion almost 
from the beginning and included clues about how to 
induce tolerance with the aid of immunosuppression. 
Clinical organ transplantation began between 1959 and 
1962 with the greater than I-year survival of six kidney 
allograft recipients, the first in Boston (1) and the next five in 
Paris (2,3). The patients had been conditioned before trans-
plantation with sublethal total body irradiation. There had 
never been a single example before 1960 of long-term sur-
vival after kidney transplantation in an animal model with 
irradiation or any other kind oftreatment. Yet, two ofthe six 
recipients (both of fraternal twin kidneys) were not treated 
with immunosuppression after transplantation and had nor-
mal renal function until their deaths more than two decades 
later. The next milestone was the function for 17 months of a 
nonrelated allograft from the time of its transplantation in 
April 1962 under azathioprine therapy, without host cytoab-
lation (4). Except for this case, however, the initial clinical 
results with drug immunosuppression were discouraging. 
In 1963, the two features of the adaptive immune response 
that eventually would make transplantation of all kinds of 
organs practical were described in the title of a report of 
kidney recipients treated at the University of Colorado (5). 
The first observation was that rejection developing under 
azathioprine was readily reversible by prednisone. The sec-
ond was" .. the subsequent development of homograft tol-
erance." The evolution of partial tolerance was inferred from 
the rapid decline of the need for immunosuppression that 
succeeded the successful reversal of rejection. The term "tol-
erance" was controversial, however, because the patients 
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were still receiving maintenance treatment. Moreover, it al-
ready had become dogma that the donor leukocyte chimer-
ism-associated mechanisms of experimental tolerance mod-
els (6,7) were not the same as those of organ engraftment. 
In fact, tolerance proved to be the bon mot. Nine (19.6%) of 
the 46 recipients of allografts from live-related donors 
treated in Colorado between the autumn of 1962 and March 
1963 had continuous graft function for most or all of the next 
four decades. One of the nine with a serum creatinine level 
less than 1.0 mg/IOO mL was recently murdered and had a 
normal transplanted kidney at coroner's autopsy; seven of 
the other eight still have good renal function after 39 to 40.5 
years. Importantly, seven of the nine patients became immu-
nosuppression free for periods ranging from 3 to 38 years 
(Fig. 1). Those who remain bear eight of the nine longest-
surviving allografts in the world today, including the four 
longest (8). 
Although a few isolated cases of uneventful prolonged drug 
discontinuance have been reported since (usually because of 
noncompliance), no comparable cluster of immunosuppres-
sion-free kidney recipients was compiled anywhere during 
the next 40 years. What was the explanation for the unique 
Denver experience? It was not a simple matter of accidental 
good histocompatibility. Although all nine of the allografts 
were from blood relatives (Fig. 1), only two were HLA 
matched, and in one of these (case 1), there was a B to A blood 
group incompatibility. 
A clue was a revision in the use of immunosuppression 
made in December 1963. Based on the results in preclinical 
studies in dogs (9), the first 45 patients had been pretreated 
with daily doses of azathioprine for 1 to 2 weeks (5). Azathio-
prine was continued after transplantation, adding pred-
nisone only when there was deterioration of initially good 
postoperative renal function. In subsequent cases, the pre-
treatment was de-emphasized because of immunosuppres-
sion-related infectious complications encountered in the pre-
operative period. A second more formal modification was 
instituted in December 1963 (10). This policy change was 
prompted by the early losses of several kidney allografts to 
nonreversible acute rejection. From this time onward, pro-
phylactic high doses of prednisone were begun at the time of 
operation, rather than as needed. 
Although better control of acute rejection was described, it 
was specifically noted that the rate of late rejection, which 
had been 5% in the original patients, rose to 30% in the 
patients treated prophylactically with steroids (10). The 
warning notation was generally unheeded, including by us. 
However, in Belfast, where the nephrologist Mary McGeown 
persisted in using azathioprine with minimum steroid inter-
vention unless specifically indicated, the best precyclosporine 
results in the world were obtained (11). Although the Belfast 
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FIGURE 1. Long-term survival and drug-free tolerance in kidney 
allograft recipients treated in 1962 to 1963. Follow-up is to May 
2003. Cr, serum creatinine. Black boxes, off immunosuppression. 
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approach was heralded by Peter Morris (Oxford), the consensus 
movement to heavy prophylactic immunosuppression was 
inexorable. 
Better drugs have resulted in a reduced use of steroids, but 
the concept of heavy early immunosuppression with multiple 
agents (often called "induction") has dominated the practice 
oftransplantation to the present day. In an important excep-
tion, CaIne et al. (12) recently treated cadaver kidney recip-
ients with a few perioperative doses of a broadly reacting 
humanized monoclonal antibody (alemtuzumab [cam-
pathR)), followed by low daily doses of cyclosporine. As in the 
earlier Colorado experience, they recognized that a signifi-
cant degree of tolerance had been achieved (called "prope 
tolerance"). 
Liver Transplantation 
Between 1965 and 1967, drug-free survival of canine liver 
recipients was reported after a short course of azathioprine 
(13) or a few perioperative doses of antilymphocyte serum or 
antilymphocyte globulin (ALG) (14). Liver transplantation 
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FIGURE 2. Rather than producing rejection (thick dashed arrows), the donor-specific immune response to allografts may be 
exhausted and deleted as depicted by the fall of the initially ascending continuous thin lines, (1) if the unmodified recipient 
response is too weak to eliminate the migratory donor cells (spontaneous tolerance models), (2) when recipient immune 
responsiveness is weakened in advance of transplantation (the pretreatment principle), or (3) when the recipient response is 
reduced into the deletable range after transplantation with just the right amount of immunosuppression. However, over· 
treatment after transplantation (shown in D with multilayered bars), reduces the efficiency and extent of clonal exhaustion-
deletion and is therefore antitolerogenic (see text for details). Tx, transplantation. 
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FIGURE 3. Current protocol of im-
munosuppression in which pre-
treatment is given with a large dose 
of a potent ALG (thymoglobulin) fol-
lowed by tacrolimus monotherapy 
to which other agents are added 
only for rejection. The inverted 
curve at the bottom shows the usu-
ally silent graft-versus-host (GVH) 
reaction. HVG, host-versus-graft. 
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with lifetime survival subsequently was demonstrated with-
out treatment in some outbred pigs (15) and in all experi-
ments with selective strain combinations of inbred rats and 
mice. Most such liver recipients accept skin or organ grafts 
from donors of the same strain but not from third-party 
donors. Importantly, similar tolerance can be induced spon-
taneously or under a brief course of immunosuppression by 
the heart and kidney but in a much more restricted number 
of strain combinations (reviewed in 16). 
In view of these experimental observations, it was not 
surprising that drug-free tolerance was observed more fre-
quently in humans after transplantation of the liver than of 
any other organ. However, significant numbers of such cases 
were compiled only in four periods. The first was the mortal-
ity-blighted decade of the 1970s when immunosuppression 
was with azathioprine (or cyclophosphamide), combined with 
a short course of pre- and postoperative ALG and the sparing 
use of prednisone (17). In 1995, 12 of our 42 patients still 
surviving from this era already had been off all immunosup-
pression for 1 to 17 years (18). These patients currently 
remain healthy for as long 33 years after transplantation, 
and many of the remaining 30 have since been weaned from 
drugs under supervision (19). 
When the exorbitant mortality and the high rate of rejec-
tion after liver transplantation declined with the advent of 
the calcineurin-inhibiting drugs, the frequency of tolerant 
liver and other organ recipients was expected to increase. 
This was seen, however, only in liver recipients treated in 
1980 to 1981 and in 1989 to 1990 during periods when cyclo-
sporine and tacrolimus were given as monotherapy and high 
doses of steroids were added only to treat rejection (19). After 
the consensus move to multiagent prophylactic immunosup-
pression from the time of transplantation, complete drug 
weaning became rare. Liver-induced tolerance emerged for 
the fourth time in the late 1990s in Kyoto, Japan (20), where 
pediatric recipients of parental livers were successfully 
weaned from steroid-sparing tacrolimus-based immunosup-
pression similar to that originally used in 1989 to 1990. 
Back to the Future 
An explanation for the diverse observations began to 
emerge with the discovery in 1992 of low-level donor leuko-
cyte chimerism in surviving human kidney, liver, and other 
kinds of organ recipients from the earlier transplant eras 
(17,21). With these observations, it was proposed that organ 
and bone marrow cell engraftment were variations on the 
same theme. In this paradigm, the two kinds of alloengraft-
ment are mirror image products of a double immune reaction, 
host-versus-graft (HVG) and graft-versus-host, in which " .. 
responses of coexisting donor and recipient cells, each to the 
other, cause reciprocal clonal exhaustion followed by periph-
eral clonal deletion .. " (17,21). 
The typically dominant HVG response of organ transplanta-
tion is induced by the preferential migration of the graft's pas-
senger leukocytes (hematolymphopoietic cells of bone marrow 
origin) to host lymphoid organs, where they induce a donor-
specific (clonal) T-cell response. The response proceeds to rejec-
tion in untreated humans and most animals. In the historical 
experimental models of spontaneous tolerance, however, the 
HVG reaction is too weak to eliminate the migratory leuko-
cytes, most commonly when the allograft is the leukocyte-rich 
liver. Therefore, the response is exhausted and deleted (Fig. 
2A). Because the exhaustion deletion is never complete, main-
tenance of the level achieved acutely (i.e., in the first 30-60 
days) depends on the persistence of peripheralized donor leu-
kocytes. The manner in which a small number of these cells 
(microchimerism) perpetuate tolerance by the combined mech-
anisms of clonal exhaustion-deletion and immune ignorance 
has been described extensively (22,23). 
The ways by which immunosuppression can permit en-
graftment in otherwise rejecting experimental models and in 
humans are depicted in Figure 2 (B and C). Ifimmunosuppres-
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sion is administered before transplantation, the antigraft re-
sponse to the organ transplant's passenger leukocytes can be 
reduced into a more readily deletable range (Fig. 2B). In some 
models, including that of irradiated human recipients of HLA-
matched bone marrow cell allografts, deletional tolerance can 
be accomplished regularly with host pretreatment only. In ret-
rospect, the kidney passenger leukocytes, combined with the 
total body irradiation used by Murray (1) and Hamburger (2) in 
their historical fraternal twin kidney recipients of 1959 were 
sufficient to induce sustained tolerance. However, less drastic 
conditioning without the risk of graft-versus-host disease is 
possible with thoracic duct drainage, total lymphoid irradiation, 
conventional antirejection drugs, and especially antilympho-
cyte serum, ALG, and other antilymphoid antibody prepara-
tions (reviewed in 24,25) (Fig. 2B). 
The antigraft response also can be rendered deletable by 
immunosuppression after the arrival of the antigen, as 
shown in Figure 2C (23). However, this is a double-edged 
sword. To the extent that antigen-specific immune activation 
is prevented, the derivative event of exhaustion-deletion may 
be reduced (Fig. 2D). As global immune activity returns in 
an initially overimmunosuppressed host, the undeleted 
clone recovers with the rest of the immune repertoire. 
Continued graft survival is then dependent on continuous 
immunosuppression. 
Two therapeutic principles of optimal immunosuppression 
derive from this view of drug-assisted tolerogenesis (23): recip-
ient pretreatment and the use of the least posttransplantation 
immunosuppression consistent with graft survival and stable 
function. In the Colorado experience of 1962 to 1963, both prin-
ciples were initially applied, but soon judged to be impractical 
because of the morbidity of pretreatment and the erratic control 
of acute rejection. When they were abandoned after 1963 and 
replaced by a philosophy of heavy immunosuppression, drug-
free kidney recipients all but disappeared. 
In contrast to the kidney, the liver (with its larger endow-
ment of migratory passenger leukocytes) continued to induce 
such tolerance in some human recipients, first under rela-
tively ineffective azathioprine-based immunosuppression. 
The additional cases that appeared with the introduction of 
cyclosporinc (1980-1981) and tacrolimus (1989-1990, and 
more recently in Japan), were reported only when these 
"modern" drugs were used in steroid-sparing regimens: that 
is, in unknowing compliance with the principle of minimal 
posttransplantation immunosuppression. 
With the greater ability to modify, reverse, and control 
rejection with today's armamentarium of potent immunosup-
pressants, we have combined both therapeutic principles for 
transplantation of the kidney, liver, pancreas, intestine, and 
lung (Fig. 3). The results suggest that recipients with a high, 
if not absolute, degree of sustained donor-specific nonreactiv-
ity (tolerance) can be systematically produced (26). 
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